2019 - 2020年实体瘤药物更新
2019-2020 Drug Updates in Solid Tumors.
作者信息
Hanna Kirollos S
机构信息
M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota.
出版信息
J Adv Pract Oncol. 2021 Apr;12(3):275-278. doi: 10.6004/jadpro.2021.12.3.11. Epub 2021 Apr 1.
Abstract
During JADPRO Live Virtual 2020, Kirollos S. Hanna, PharmD, BCPS, BCOP, updated the audience on the pharmacology, new indications, and the clinical trial data of novel medications as well as expanded indications in solid tumors. Dr. Hanna also discussed signs and symptoms of potential serious and life-threatening adverse events, and how new therapeutic entities will impact the advanced practice setting.
摘要
在2020年JADPRO现场虚拟会议期间，药学博士、BCPS、BCOP的基罗洛斯·S·汉纳向观众介绍了新型药物的药理学、新适应症、临床试验数据以及实体瘤中的扩展适应症。汉纳博士还讨论了潜在严重和危及生命的不良事件的体征和症状，以及新治疗实体将如何影响高级实践环境。
相似文献
1
2019-2020 Drug Updates in Solid Tumors.2019 - 2020年实体瘤药物更新
J Adv Pract Oncol. 2021 Apr;12(3):275-278. doi: 10.6004/jadpro.2021.12.3.11. Epub 2021 Apr 1.
2
2021-2022 Drug Updates in Solid Tumors.2021 - 2022年实体瘤药物更新
J Adv Pract Oncol. 2023 Apr;14(3):227-231. doi: 10.6004/jadpro.2023.14.3.9. Epub 2023 Apr 1.
3
2020-2021 Drug Updates in Hematologic Malignancies.2020 - 2021年血液系统恶性肿瘤的药物更新
J Adv Pract Oncol. 2022 Apr;13(3):282-285. doi: 10.6004/Jadpro.2022.13.3.20. Epub 2022 May 23.
4
2019-2020 Drug Updates in Hematologic Malignancies.2019 - 2020年血液系统恶性肿瘤的药物更新
J Adv Pract Oncol. 2021 Apr;12(3):279-283. doi: 10.6004/jadpro.2021.12.3.12. Epub 2021 Apr 1.
5
2020-2021 Drug Updates in Solid Tumors.2020 - 2021年实体瘤药物更新
J Adv Pract Oncol. 2022 Apr;13(3):275-281. doi: 10.6004/jadpro.2022.13.3.19. Epub 2022 May 23.
6
2020-2021 Drug Updates: Investigational Therapeutics in the Pipeline.2020 - 2021年药物更新：正在研发的研究性疗法
J Adv Pract Oncol. 2022 Apr;13(3):286-291. doi: 10.6004/jadpro.2022.13.3.21. Epub 2022 May 23.
7
2022-2023 Drug Updates in Solid Tumors.2022 - 2023年实体瘤药物更新
J Adv Pract Oncol. 2024 Apr;15(3):170-176. doi: 10.6004/jadpro.2024.15.3.3. Epub 2024 Apr 1.
8
2021-2022 Drug Updates: Investigational Therapeutics in the Pipeline.2021 - 2022药物更新：正在研发中的研究性疗法
J Adv Pract Oncol. 2023 Apr;14(3):237-240. doi: 10.6004/jadpro.2023.14.3.11. Epub 2023 Apr 1.
9
2018-2019 Drug Updates in Solid Tumors.2018 - 2019年实体瘤药物更新
J Adv Pract Oncol. 2020 Apr;11(3):255-258. doi: 10.6004/jadpro.2020.11.3.8. Epub 2020 Apr 1.
10
2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline.2022 - 2023药物更新：正在研发中的试验性疗法
J Adv Pract Oncol. 2024 Apr;15(3):182-185. doi: 10.6004/jadpro.2024.15.3.5. Epub 2024 Apr 1.
本文引用的文献
1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
2
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.在铂类和抗程序性死亡 1/程序性死亡配体 1 治疗后，依维莫司丁治疗尿路上皮癌的关键试验。
J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29.
3
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan-hziy 治疗难治性转移性三阴性乳腺癌。
N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.
Zotero 插件